SHWETA MAURYA

Ms. SHWETA MAURYA

School of pharmacy, Hebrew University of Jerusalem, Jerusalem, Southern, Israel
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
ASAseel Saadi
Aseel Saadi
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Oxidative stress is a pivotal driver of epileptogenesis and seizure-induced neuronal pathology, with NADPH oxidase 2 (NOX2) serving as a major source of reactive oxygen species (ROS) in the brain. Despite its established role in seizure pathophysiology, the therapeutic implications of selective NOX2 inhibition in epilepsy remain insufficiently explored. Here, we investigate the effect of GSK2795039, a potent NOX2 inhibitor, using both in vitro and in vivo epilepsy models. In vitro, mixed cortical neuroglial cultures were treated with 4-aminopyridine (4-AP) and picrotoxin (PTX) to induce epileptiform activity. Calcium imaging and dihydroethidium (DHE) fluorescence assays revealed that GSK2795039 significantly reduced synchronous Ca2+ oscillations and ROS accumulation. In vivo, adult rats implanted with ECoG transmitters were pretreated with GSK2795039 prior to pentylenetetrazol (PTZ) administration to evoke seizures. ECoG recording and behavioral seizure scoring showed that GSK2795039 pretreatment inhibited the seizure severity, duration and cumulative seizure burden. Molecular analyses, including quantitative PCR and western blotting, revealed a significant downregulation of NOX2 mRNA in both the hippocampus and cortex, although protein levels remained unchanged. Additionally, immunofluorescence and histological staining confirmed that GSK2795039 mitigated oxidative DNA damage, preserved hippocampal neuronal integrity, and differentially modulated pro- and anti-inflammatory cytokine expression. These findings underscore NOX2 inhibition as a compelling neuroprotective strategy and highlight the potential of GSK2795039 to suppress oxidative and inflammatory cascades in epilepsy. Targeting NOX2 may represent a promising avenue for precision therapeutics in oxidative stress-driven epilepsy.

19 August 2025 in Redox Biology
Verified
Journal Article
Open access
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
ASAseel Saadi
Aseel Saadi
TZTaige Zhang
Taige Zhang
ALAndreas Lieb
Andreas Lieb
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Epilepsy, a chronic neurological disorder affecting approximately 1 % of the global population, is characterized by recurrent seizures that are often refractory to current antiseizure medications (ASMs). These pharmacotherapies predominantly suppress symptoms without intervening in the underlying pathophysiological cascade, which includes persistent oxidative stress and neuroinflammation, key drivers of epileptogenesis and pharmacoresistance. Among the primary enzymatic sources of reactive oxygen species (ROS), NADPH oxidase 2 (NOX2) has emerged as a central mediator of redox imbalance and neuroimmune activation in the brain. However, the sex-specific roles of NOX2 and its modulation as a therapeutic strategy remain largely unexplored. Here, we investigated the therapeutic efficacy of GSK2795039, a selective and functionally active NOX2 inhibitor, in a kainic acid (KA)-induced status epilepticus (SE) rat model. We examined both acute and chronic outcomes of early NOX2 inhibition on oxidative stress, neuroinflammation, hippocampal neurodegeneration, and cognitive function, incorporating rigorous analysis of sex-dependent responses. Long-term effects on epileptogenesis were assessed using continuous 24/7 video-electrocorticographic (vECoG) monitoring. Our results revealed that early GSK2795039 intervention significantly attenuated SE-induced oxidative damage, pro-inflammatory cytokine expression, and neuronal death, thereby mitigating the development of spontaneous recurrent seizures. Notably, male rats exhibited a more robust therapeutic response, including a marked reduction in seizure burden and improved cognitive performance, whereas females displayed a more modest response, suggesting the presence of compensatory or NOX2-independent antioxidant mechanisms. These findings underscore the pivotal role of NOX2-derived ROS in driving epileptogenesis and highlight the translational potential of NOX2-targeted therapies. Importantly, our study revealed a clear sex divergence in therapeutic outcomes, reinforcing the necessity of integrating sex as a critical biological variable in preclinical and clinical strategies aimed at disease modification in epilepsy.

10 January 2026 in Redox Biology
Verified
Journal Article
Open access
PSPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
ASAseel Saadi
Aseel Saadi
SSSereen Sandouka
Sereen Sandouka
TZTaige Zhang
Taige Zhang
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, in which oxidative stress and neuroinflammation play central roles in driving disease progression and pharmacoresistance. Approximately 30-40 % of patients are resistant to current antiseizure medications, which suppress symptoms but do not prevent epilepsy development or modify its progression. There is an urgent need for therapies with true disease-modifying potential. TXM-CB3 (CB3), a thioredoxin-mimetic tripeptide, has been reported to modulate redox and inflammatory pathways. In this study, we evaluated the therapeutic potential of CB3 in preclinical models of temporal lobe epilepsy, focusing on its capacity to suppress seizures, preserve neuronal integrity, and mitigate epilepsy-associated behavioral impairments. We first examined CB3 in an in vitro model of low-Mg2+-induced epileptiform activity, where pretreatment with CB3 (50, 100 μM) attenuated oxidative activity and reduced proinflammatory cytokine expression (IL-6, IL-1β, TNF-α), while enhancing IL-10 levels. In vivo, early CB3 intervention (20 mg/kg/day, i.p.) following kainic acid-induced status epilepticus significantly delayed seizure onset, reduced seizure frequency and cumulative burden, and preserved hippocampal neuronal integrity. Treated animals also showed improved locomotor activity, reduced anxiety-like behavior, and better performance in spatial working memory tasks. In established chronic epilepsy, CB3 treatment (20 mg/kg/day, i.p.) produced a sustained reduction in recurrent seizure activity and seizure burden, with additional effects on anxiety-like behavior, though memory and learning deficits remained unchanged. Together, these findings highlight CB3's potential as a disease-modifying therapy. By reducing seizure recurrence, preserving neuronal integrity, and alleviating selected behavioral impairments, CB3 offers therapeutic benefits that extend beyond conventional ASMs and warrants further investigation for translation into clinical epilepsy treatment.

10 April 2025 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
ASAseel Saadi
Aseel Saadi
SSSereen Sandouka
Sereen Sandouka
TZTaige Zhang
Taige Zhang
TSTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, frequently driven by oxidative stress and neuroinflammation, which not only exacerbate disease progression but also contribute to pharmacoresistance. Despite the widespread use of anti-seizure medications, approximately 30–40% of patients remain refractory to treatment, underscoring the urgent need for novel therapeutic interventions that target underlying pathophysiological mechanisms. In this study, we investigated the thioredoxin-mimetic tripeptide TXM-CB3 (CB3), previously demonstrated to attenuate oxidative stress and neuroinflammatory cascades, as a disease-modifying agent for epilepsy. Initially, we evaluated the efficacy of CB3 in an in vitro epileptiform activity model to assess its capacity to suppress reactive oxygen species production and modulate inflammatory cytokine expression. Subsequently, we conducted two simultaneous preclinical trials to determine the anti-epileptogenic and anti-epileptic potential of CB3 while also assessing its neuroprotective effects against epilepsy-associated cognitive deficits and neuronal injury. Our findings reveal that CB3 significantly suppresses ROS generation and the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) while enhancing anti-inflammatory IL-10 expression during epileptiform activity in vitro. In vivo, CB3 markedly reduced seizure frequency, prolonged seizure latency, and mitigated cumulative seizure burden. Furthermore, CB3 conferred neuroprotection by preserving hippocampal neuronal integrity, attenuating oxidative-induced DNA/RNA damage, and ameliorating spatial memory deficits and anxiety-like behaviors. Notably, CB3 exhibited sustained therapeutic efficacy in the chronic phase of epilepsy without affecting locomotion or recognition memory. Collectively, our findings position CB3 as a potent disease-modifying therapeutic that disrupts the self-perpetuating cycle of oxidative stress and neuroinflammation, thereby reducing seizure burden and preserving neuronal function.

28 February 2025
Verified
Book Chapter
Closed access
PDF file
ASAnshul Shakya
Anshul Shakya
BDBhargab Deka
Bhargab Deka
SKShuby Kumari
Shuby Kumari
SCSushil Kumar Chaudhary
Sushil Kumar Chaudhary
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
SGSurajit Kumar Ghosh
Surajit Kumar Ghosh
Natural bioactive compounds have become increasingly popular in research to explore their potential in the treatment of Alzheimer’s and other forms of dementia. Bioactive compounds are derived from natural sources, such as medicinal plants, and have been studied for their antioxidant, anti-inflammatory, and neuroprotective properties. Numerous studies have indicated that these compounds can play a role in reducing the progression of Alzheimer’s and other forms of dementia, as well as improving cognitive function. In particular, polyphenols have been studied for their ability to reduce oxidative damage and inflammation in the brain. Polyphenols are a diverse group of compounds that are found naturally in many fruits, vegetables, and herbs, and are known for their potent antioxidant properties. Studies have shown that polyphenols can inhibit the formation of amyloid plaques, which is a major hallmark of Alzheimer’s disease. Other natural bioactive compounds that have been studied for their potential to treat Alzheimer’s and other forms of dementia include omega-3 fatty acids, curcumin, and resveratrol. Omega-3 fatty acids have been shown to have anti-inflammatory and neuroprotective effects, while curcumin has been studied for its ability to reduce amyloid plaque formation and improve cognitive function. Resveratrol, a compound found in red wine, has also been studied for its potential to reduce inflammation and improve cognitive function. Overall, natural bioactive compounds have great potential to treat Alzheimer’s and other dementias. Using natural bioactive compounds is a promising area of research for treating Alzheimer’s and other forms of dementia. While further research is needed to confirm the efficacy of these compounds, the preliminary evidence suggests that they may offer a safe and effective way to reduce cognitive impairment and improve the quality of life for those affected by dementia. <!----> <!----> <!----> <!---->

7 October 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
YSYara Sheeni
Yara Sheeni
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
SSSereen Sandouka
Sereen Sandouka
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
We aimed to investigate the acute anticonvulsant and long-term antiepileptogenic effects of the synthetic triterpenoid CDDO-EA in complementary experimental models of epilepsy. CDDO-EA was evaluated in the pentylenetetrazol seizure model and a kainic acid-induced post-status epilepticus model. Acute seizure severity, latency to generalized seizures, oxidative stress and inflammatory markers, spontaneous recurrent seizures, and hippocampal neuronal survival were assessed. In the pentylenetetrazol model, CDDO-EA pretreatment reduced maximal seizure severity and prolonged the latency to stage V-VI seizures. These effects were associated with decreased inflammatory cytokine levels and malondialdehyde levels, alongside increased superoxide dismutase and catalase activities 24 h after pentylenetetrazol administration. In the post-status epilepticus model, two weeks of CDDO-EA treatment significantly delayed the onset of spontaneous recurrent seizures and produced sustained reductions in weekly seizure frequency and cumulative seizure burden. Histological analysis demonstrated greater neuronal preservation in the hippocampal CA1 and CA3 regions of CDDO-EA-treated animals compared with vehicle controls. CDDO-EA exerts both anticonvulsant and disease-modifying effects by attenuating seizure severity, restoring redox-inflammatory homeostasis, preserving hippocampal neurons, and suppressing epileptogenesis after status epilepticus, supporting its therapeutic potential as a novel strategy for epilepsy.